-
1
-
-
51649115383
-
Mast cells and mastocytosis
-
Metcalfe D.D. Mast cells and mastocytosis. Blood 2008, 112(4):946-956.
-
(2008)
Blood
, vol.112
, Issue.4
, pp. 946-956
-
-
Metcalfe, D.D.1
-
2
-
-
34249333084
-
Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria
-
Valent P., Akin C., Escribano L., et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest 2007, 37(6):435-453.
-
(2007)
Eur J Clin Invest
, vol.37
, Issue.6
, pp. 435-453
-
-
Valent, P.1
Akin, C.2
Escribano, L.3
-
3
-
-
0034983045
-
Diagnostic criteria and classification of mastocytosis: a consensus proposal
-
Valent P., Horny H.P., Escribano L., et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 2001, 25(7):603-625.
-
(2001)
Leuk Res
, vol.25
, Issue.7
, pp. 603-625
-
-
Valent, P.1
Horny, H.P.2
Escribano, L.3
-
5
-
-
84884541237
-
Mastocytosis: update on pharmacotherapy and future directions
-
Cardet J.C., Akin C., Lee M.J. Mastocytosis: update on pharmacotherapy and future directions. Expert Opin Pharmacother 2013, 14(15):2033-2045.
-
(2013)
Expert Opin Pharmacother
, vol.14
, Issue.15
, pp. 2033-2045
-
-
Cardet, J.C.1
Akin, C.2
Lee, M.J.3
-
7
-
-
37749039528
-
Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients
-
Brockow K., Jofer C., Behrendt H., et al. Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients. Allergy 2008, 63(2):226-232.
-
(2008)
Allergy
, vol.63
, Issue.2
, pp. 226-232
-
-
Brockow, K.1
Jofer, C.2
Behrendt, H.3
-
8
-
-
84883214095
-
KIT D816V mutation burden does not correlate to clinical manifestations of indolent systemic mastocytosis
-
Broesby-Olsen S., Kristensen T., Vestergaard H., et al. KIT D816V mutation burden does not correlate to clinical manifestations of indolent systemic mastocytosis. JAllergy Clin Immunol 2013, 132(3):723-728.
-
(2013)
JAllergy Clin Immunol
, vol.132
, Issue.3
, pp. 723-728
-
-
Broesby-Olsen, S.1
Kristensen, T.2
Vestergaard, H.3
-
9
-
-
84895061744
-
-
Nonaggressive systemic mastocytosis (SM) without skin lesions associated with insect-induced anaphylaxis shows unique features versus other indolent SM.
-
Alvarez-Twose I, Zanotti R, Gonzalez-de-Olano D, et al. Nonaggressive systemic mastocytosis (SM) without skin lesions associated with insect-induced anaphylaxis shows unique features versus other indolent SM. 2014;133(2):520-8.
-
(2014)
, vol.133
, Issue.2
, pp. 520-528
-
-
Alvarez-Twose, I.1
Zanotti, R.2
Gonzalez-de-Olano, D.3
-
10
-
-
84885735607
-
Anaphylaxis caused by mosquito allergy in systemic mastocytosis
-
Reiter N., Reiter M., Altrichter S., et al. Anaphylaxis caused by mosquito allergy in systemic mastocytosis. Lancet 2013, 382(9901):1380.
-
(2013)
Lancet
, vol.382
, Issue.9901
, pp. 1380
-
-
Reiter, N.1
Reiter, M.2
Altrichter, S.3
-
11
-
-
67651120132
-
Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors
-
Lim K.H., Tefferi A., Lasho T.L., et al. Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood 2009, 113(23):5727-5736.
-
(2009)
Blood
, vol.113
, Issue.23
, pp. 5727-5736
-
-
Lim, K.H.1
Tefferi, A.2
Lasho, T.L.3
-
12
-
-
84890562829
-
Primary mast cell disorders in children
-
Fried A.J., Akin C. Primary mast cell disorders in children. Curr Allergy Asthma Rep 2013, 13(6):693-701.
-
(2013)
Curr Allergy Asthma Rep
, vol.13
, Issue.6
, pp. 693-701
-
-
Fried, A.J.1
Akin, C.2
-
13
-
-
84863115159
-
Childhood-onset mastocytosis
-
[in German]
-
Siebenhaar F., Weller K., Blume-Peytavi U., et al. Childhood-onset mastocytosis. Hautarzt 2012, 63(2):104-109. [in German].
-
(2012)
Hautarzt
, vol.63
, Issue.2
, pp. 104-109
-
-
Siebenhaar, F.1
Weller, K.2
Blume-Peytavi, U.3
-
14
-
-
0036202127
-
Cutaneous mastocytosis-clinical heterogeneity
-
Hartmann K., Henz B.M. Cutaneous mastocytosis-clinical heterogeneity. Int Arch Allergy Immunol 2002, 127(2):143-146.
-
(2002)
Int Arch Allergy Immunol
, vol.127
, Issue.2
, pp. 143-146
-
-
Hartmann, K.1
Henz, B.M.2
-
15
-
-
77953100303
-
Cutaneous mastocytosis: two pediatric cases treated with topical pimecrolimus
-
Correia O., Duarte A.F., Quirino P., et al. Cutaneous mastocytosis: two pediatric cases treated with topical pimecrolimus. Dermatol Online J 2010, 16(5):8.
-
(2010)
Dermatol Online J
, vol.16
, Issue.5
, pp. 8
-
-
Correia, O.1
Duarte, A.F.2
Quirino, P.3
-
17
-
-
84873095618
-
Response of urticaria pigmentosa to cladribine in a patient with systemic mastocytosis
-
Bennett M., Chubar Y. Response of urticaria pigmentosa to cladribine in a patient with systemic mastocytosis. Br J Haematol 2013, 160(4):420.
-
(2013)
Br J Haematol
, vol.160
, Issue.4
, pp. 420
-
-
Bennett, M.1
Chubar, Y.2
-
18
-
-
80051475544
-
Tyrosine kinase inhibitors in the treatment of systemic mastocytosis
-
Ustun C., DeRemer D.L., Akin C. Tyrosine kinase inhibitors in the treatment of systemic mastocytosis. Leuk Res 2011, 35(9):1143-1152.
-
(2011)
Leuk Res
, vol.35
, Issue.9
, pp. 1143-1152
-
-
Ustun, C.1
DeRemer, D.L.2
Akin, C.3
-
19
-
-
0141956431
-
Ultraviolet irradiation induces apoptosis in human immature, but not in skin mast cells
-
Guhl S., Hartmann K., Tapkenhinrichs S., et al. Ultraviolet irradiation induces apoptosis in human immature, but not in skin mast cells. JInvest Dermatol 2003, 121(4):837-844.
-
(2003)
JInvest Dermatol
, vol.121
, Issue.4
, pp. 837-844
-
-
Guhl, S.1
Hartmann, K.2
Tapkenhinrichs, S.3
-
20
-
-
0033890342
-
The treatment of urticaria pigmentosa with the frequency-doubled Q-switch Nd:YAG laser
-
Bedlow A.J., Gharrie S., Harland C.C. The treatment of urticaria pigmentosa with the frequency-doubled Q-switch Nd:YAG laser. JCutan Laser Ther 2000, 2(1):45-47.
-
(2000)
JCutan Laser Ther
, vol.2
, Issue.1
, pp. 45-47
-
-
Bedlow, A.J.1
Gharrie, S.2
Harland, C.C.3
-
21
-
-
55249087258
-
The cosmetic treatment of urticaria pigmentosa with Nd:YAG laser at 532 nanometers
-
Resh B., Jones E., Glaser D.A. The cosmetic treatment of urticaria pigmentosa with Nd:YAG laser at 532 nanometers. JCosmet Dermatol 2005, 4(2):78-82.
-
(2005)
JCosmet Dermatol
, vol.4
, Issue.2
, pp. 78-82
-
-
Resh, B.1
Jones, E.2
Glaser, D.A.3
-
22
-
-
84880260205
-
Rupatadine improves quality of life in mastocytosis: a randomized, double-blind, placebo-controlled trial
-
Siebenhaar F., Fortsch A., Krause K., et al. Rupatadine improves quality of life in mastocytosis: a randomized, double-blind, placebo-controlled trial. Allergy 2013, 68(7):949-952.
-
(2013)
Allergy
, vol.68
, Issue.7
, pp. 949-952
-
-
Siebenhaar, F.1
Fortsch, A.2
Krause, K.3
-
23
-
-
61549112485
-
High-dose desloratadine decreases wheal volume and improves cold provocation thresholds compared with standard-dose treatment in patients with acquired cold urticaria: a randomized, placebo-controlled, crossover study
-
Siebenhaar F., Degener F., Zuberbier T., et al. High-dose desloratadine decreases wheal volume and improves cold provocation thresholds compared with standard-dose treatment in patients with acquired cold urticaria: a randomized, placebo-controlled, crossover study. JAllergy Clin Immunol 2009, 123(3):672-679.
-
(2009)
JAllergy Clin Immunol
, vol.123
, Issue.3
, pp. 672-679
-
-
Siebenhaar, F.1
Degener, F.2
Zuberbier, T.3
-
24
-
-
80052349904
-
H1-antihistamine up-dosing in chronic spontaneous urticaria: patients' perspective of effectiveness and side effects-a retrospective survey study
-
Weller K., Ziege C., Staubach P., et al. H1-antihistamine up-dosing in chronic spontaneous urticaria: patients' perspective of effectiveness and side effects-a retrospective survey study. PloS One 2011, 6(9):e23931.
-
(2011)
PloS One
, vol.6
, Issue.9
-
-
Weller, K.1
Ziege, C.2
Staubach, P.3
-
25
-
-
70349210289
-
EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria
-
Zuberbier T., Asero R., Bindslev-Jensen C., et al. EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria. Allergy 2009, 64(10):1427-1443.
-
(2009)
Allergy
, vol.64
, Issue.10
, pp. 1427-1443
-
-
Zuberbier, T.1
Asero, R.2
Bindslev-Jensen, C.3
-
26
-
-
79960211070
-
Oral and topical sodium cromoglicate in the treatment of diffuse cutaneous mastocytosis in an infant
-
Accessed June 29, 2011
-
Edwards A.M., Capkova S. Oral and topical sodium cromoglicate in the treatment of diffuse cutaneous mastocytosis in an infant. BMJ Case Rep 2011, Accessed June 29, 2011. 10.1136/bcr.02.2011.3910.
-
(2011)
BMJ Case Rep
-
-
Edwards, A.M.1
Capkova, S.2
-
27
-
-
76949102630
-
Topical sodium cromoglicate relieves allergen- and histamine-induced dermal pruritus
-
Vieira Dos Santos R., Magerl M., Martus P., et al. Topical sodium cromoglicate relieves allergen- and histamine-induced dermal pruritus. Br J Dermatol 2010, 162(3):674-676.
-
(2010)
Br J Dermatol
, vol.162
, Issue.3
, pp. 674-676
-
-
Vieira Dos Santos, R.1
Magerl, M.2
Martus, P.3
-
28
-
-
0027217619
-
Absorption mechanism of 1,3-bis(2-ethoxycarbonylchromon-5-yloxy)-2-((S)-lysyloxy)propane dihydrochloride (N-556), a prodrug for the oral delivery of disodium cromoglycate
-
Yoshimi A., Hashizume H., Kitagawa M., et al. Absorption mechanism of 1,3-bis(2-ethoxycarbonylchromon-5-yloxy)-2-((S)-lysyloxy)propane dihydrochloride (N-556), a prodrug for the oral delivery of disodium cromoglycate. Biol Pharm Bull 1993, 16(4):375-378.
-
(1993)
Biol Pharm Bull
, vol.16
, Issue.4
, pp. 375-378
-
-
Yoshimi, A.1
Hashizume, H.2
Kitagawa, M.3
-
29
-
-
0026511136
-
Inhibition profiles of sodium cromoglycate and nedocromil sodium on mediator release from mast cells of human skin, lung, tonsil, adenoid and intestine
-
Okayama Y., Benyon R.C., Rees P.H., et al. Inhibition profiles of sodium cromoglycate and nedocromil sodium on mediator release from mast cells of human skin, lung, tonsil, adenoid and intestine. Clin Exp Allergy 1992, 22(3):401-409.
-
(1992)
Clin Exp Allergy
, vol.22
, Issue.3
, pp. 401-409
-
-
Okayama, Y.1
Benyon, R.C.2
Rees, P.H.3
-
30
-
-
33747519112
-
Mast cell mediators in allergic inflammation and mastocytosis
-
Castells M. Mast cell mediators in allergic inflammation and mastocytosis. Immunol Allergy Clin North Am 2006, 26(3):465-485.
-
(2006)
Immunol Allergy Clin North Am
, vol.26
, Issue.3
, pp. 465-485
-
-
Castells, M.1
-
31
-
-
0023877762
-
Treatment of adult systemic mastocytosis with a PAF-acether antagonist BN52063
-
Guinot P., Summerhayes C., Berdah L., et al. Treatment of adult systemic mastocytosis with a PAF-acether antagonist BN52063. Lancet 1988, 2(8602):114.
-
(1988)
Lancet
, vol.2
, Issue.8602
, pp. 114
-
-
Guinot, P.1
Summerhayes, C.2
Berdah, L.3
-
32
-
-
0024343550
-
Occurrence of platelet-activating factor (PAF) and an endogenous inhibitor of platelet aggregation in diffuse cutaneous mastocytosis
-
Macpherson J.L., Kemp A., Rogers M., et al. Occurrence of platelet-activating factor (PAF) and an endogenous inhibitor of platelet aggregation in diffuse cutaneous mastocytosis. Clin Exp Immunol 1989, 77(3):391-396.
-
(1989)
Clin Exp Immunol
, vol.77
, Issue.3
, pp. 391-396
-
-
Macpherson, J.L.1
Kemp, A.2
Rogers, M.3
-
33
-
-
84859109120
-
Refractory symptoms successfully treated with leukotriene inhibition in a child with systemic mastocytosis
-
Turner P.J., Kemp A.S., Rogers M., et al. Refractory symptoms successfully treated with leukotriene inhibition in a child with systemic mastocytosis. Pediatr Dermatol 2012, 29(2):222-223.
-
(2012)
Pediatr Dermatol
, vol.29
, Issue.2
, pp. 222-223
-
-
Turner, P.J.1
Kemp, A.S.2
Rogers, M.3
-
34
-
-
0033946286
-
Gastrointestinal abnormalities and involvement in systemic mastocytosis
-
Jensen R.T. Gastrointestinal abnormalities and involvement in systemic mastocytosis. Hematol Oncol Clin North Am 2000, 14(3):579-623.
-
(2000)
Hematol Oncol Clin North Am
, vol.14
, Issue.3
, pp. 579-623
-
-
Jensen, R.T.1
-
35
-
-
84884904326
-
Gastrointestinal manifestations in mastocytosis: a study of 83 patients
-
e1-3
-
Sokol H., Georgin-Lavialle S., Canioni D., et al. Gastrointestinal manifestations in mastocytosis: a study of 83 patients. JAllergy Clin Immunol 2013, 132(4):866-873.e1-3.
-
(2013)
JAllergy Clin Immunol
, vol.132
, Issue.4
, pp. 866-873
-
-
Sokol, H.1
Georgin-Lavialle, S.2
Canioni, D.3
-
36
-
-
33646051264
-
Current options in the treatment of mast cell mediator-related symptoms in mastocytosis
-
Escribano L., Akin C., Castells M., et al. Current options in the treatment of mast cell mediator-related symptoms in mastocytosis. Inflamm Allergy Drug Targets 2006, 5(1):61-77.
-
(2006)
Inflamm Allergy Drug Targets
, vol.5
, Issue.1
, pp. 61-77
-
-
Escribano, L.1
Akin, C.2
Castells, M.3
-
37
-
-
0034992893
-
Mastocytosis: molecular mechanisms and clinical disease heterogeneity
-
Metcalfe D.D., Akin C. Mastocytosis: molecular mechanisms and clinical disease heterogeneity. Leuk Res 2001, 25(7):577-582.
-
(2001)
Leuk Res
, vol.25
, Issue.7
, pp. 577-582
-
-
Metcalfe, D.D.1
Akin, C.2
-
38
-
-
84862683302
-
Evidence for cognitive impairment in mastocytosis: prevalence, features and correlations to depression
-
Moura D.S., Sultan S., Georgin-Lavialle S., et al. Evidence for cognitive impairment in mastocytosis: prevalence, features and correlations to depression. PloS One 2012, 7(6):e39468.
-
(2012)
PloS One
, vol.7
, Issue.6
-
-
Moura, D.S.1
Sultan, S.2
Georgin-Lavialle, S.3
-
39
-
-
80054848122
-
Depression in patients with mastocytosis: prevalence, features and effects of masitinib therapy
-
Moura D.S., Sultan S., Georgin-Lavialle S., et al. Depression in patients with mastocytosis: prevalence, features and effects of masitinib therapy. PloS One 2011, 6(10):e26375.
-
(2011)
PloS One
, vol.6
, Issue.10
-
-
Moura, D.S.1
Sultan, S.2
Georgin-Lavialle, S.3
-
40
-
-
0022538802
-
Mixed organic brain syndrome as a manifestation of systemic mastocytosis
-
Rogers M.P., Bloomingdale K., Murawski B.J., et al. Mixed organic brain syndrome as a manifestation of systemic mastocytosis. Psychosom Med 1986, 48(6):437-447.
-
(1986)
Psychosom Med
, vol.48
, Issue.6
, pp. 437-447
-
-
Rogers, M.P.1
Bloomingdale, K.2
Murawski, B.J.3
-
41
-
-
0018687287
-
Oral disodium cromoglycate in the treatment of systemic mastocytosis
-
Soter N.A., Austen K.F., Wasserman S.I. Oral disodium cromoglycate in the treatment of systemic mastocytosis. NEngl J Med 1979, 301(9):465-469.
-
(1979)
NEngl J Med
, vol.301
, Issue.9
, pp. 465-469
-
-
Soter, N.A.1
Austen, K.F.2
Wasserman, S.I.3
-
42
-
-
0025302361
-
Cromolyn sodium in the management of systemic mastocytosis
-
Horan R.F., Sheffer A.L., Austen K.F. Cromolyn sodium in the management of systemic mastocytosis. JAllergy Clin Immunol 1990, 85(5):852-855.
-
(1990)
JAllergy Clin Immunol
, vol.85
, Issue.5
, pp. 852-855
-
-
Horan, R.F.1
Sheffer, A.L.2
Austen, K.F.3
-
43
-
-
0024579966
-
The effect of disodium cromoglycate and ketotifen on the excretion of histamine and N tau-methylimidazole acetic acid in urine of patients with mastocytosis
-
Mallet A.I., Norris P., Rendell N.B., et al. The effect of disodium cromoglycate and ketotifen on the excretion of histamine and N tau-methylimidazole acetic acid in urine of patients with mastocytosis. Br J Clin Pharmacol 1989, 27(1):88-91.
-
(1989)
Br J Clin Pharmacol
, vol.27
, Issue.1
, pp. 88-91
-
-
Mallet, A.I.1
Norris, P.2
Rendell, N.B.3
-
44
-
-
0028068094
-
Radiotherapy of refractory bone pain due to systemic mast cell disease
-
Johnstone P.A., Mican J.M., Metcalfe D.D., et al. Radiotherapy of refractory bone pain due to systemic mast cell disease. Am J Clin Oncol 1994, 17(4):328-330.
-
(1994)
Am J Clin Oncol
, vol.17
, Issue.4
, pp. 328-330
-
-
Johnstone, P.A.1
Mican, J.M.2
Metcalfe, D.D.3
-
45
-
-
62849113861
-
Survey of aspirin administration in systemic mastocytosis
-
Butterfield J.H. Survey of aspirin administration in systemic mastocytosis. Prostaglandins Other Lipid Mediat 2009, 88(3-4):122-124.
-
(2009)
Prostaglandins Other Lipid Mediat
, vol.88
, Issue.3-4
, pp. 122-124
-
-
Butterfield, J.H.1
-
46
-
-
0033945410
-
Treatment of systemic mast cell disorders
-
vii
-
Worobec A.S. Treatment of systemic mast cell disorders. Hematol Oncol Clin North Am 2000, 14(3):659-687. vii.
-
(2000)
Hematol Oncol Clin North Am
, vol.14
, Issue.3
, pp. 659-687
-
-
Worobec, A.S.1
-
47
-
-
0036210051
-
Mastocytosis: current treatment concepts
-
Worobec A.S., Metcalfe D.D. Mastocytosis: current treatment concepts. Int Arch Allergy Immunol 2002, 127(2):153-155.
-
(2002)
Int Arch Allergy Immunol
, vol.127
, Issue.2
, pp. 153-155
-
-
Worobec, A.S.1
Metcalfe, D.D.2
-
48
-
-
19544379538
-
Systemic mastocytosis: a rare cause of osteoporosis and its response to bisphosphonate treatment
-
Lim A.Y., Ostor A.J., Love S., et al. Systemic mastocytosis: a rare cause of osteoporosis and its response to bisphosphonate treatment. Ann Rheum Dis 2005, 64(6):965-966.
-
(2005)
Ann Rheum Dis
, vol.64
, Issue.6
, pp. 965-966
-
-
Lim, A.Y.1
Ostor, A.J.2
Love, S.3
-
49
-
-
77953105527
-
Omalizumab is effective in treating systemic mastocytosis in a nonatopic patient
-
Douglass J.A., Carroll K., Voskamp A., et al. Omalizumab is effective in treating systemic mastocytosis in a nonatopic patient. Allergy 2010, 65(7):926-927.
-
(2010)
Allergy
, vol.65
, Issue.7
, pp. 926-927
-
-
Douglass, J.A.1
Carroll, K.2
Voskamp, A.3
-
50
-
-
84885950853
-
Short-term omalizumab treatment in an adolescent with cutaneous mastocytosis
-
Matito A., Blazquez-Goni C., Morgado J.M., et al. Short-term omalizumab treatment in an adolescent with cutaneous mastocytosis. Ann Allergy Asthma Immunol 2013, 111(5):425-426.
-
(2013)
Ann Allergy Asthma Immunol
, vol.111
, Issue.5
, pp. 425-426
-
-
Matito, A.1
Blazquez-Goni, C.2
Morgado, J.M.3
-
51
-
-
34250826484
-
Successful treatment of cutaneous mastocytosis and Meniere disease with anti-IgE therapy
-
Siebenhaar F., Kuhn W., Zuberbier T., et al. Successful treatment of cutaneous mastocytosis and Meniere disease with anti-IgE therapy. JAllergy Clin Immunol 2007, 120(1):213-215.
-
(2007)
JAllergy Clin Immunol
, vol.120
, Issue.1
, pp. 213-215
-
-
Siebenhaar, F.1
Kuhn, W.2
Zuberbier, T.3
-
52
-
-
84874732930
-
Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria
-
Maurer M., Rosen K., Hsieh H.J., et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. NEngl J Med 2013, 368(10):924-935.
-
(2013)
NEngl J Med
, vol.368
, Issue.10
, pp. 924-935
-
-
Maurer, M.1
Rosen, K.2
Hsieh, H.J.3
-
53
-
-
77955921599
-
Successful treatment of idiopathic anaphylaxis in an adolescent
-
[author reply: 6]
-
Pitt T.J., Cisneros N., Kalicinsky C., et al. Successful treatment of idiopathic anaphylaxis in an adolescent. JAllergy Clin Immunol 2010, 126(2):415-416. [author reply: 6].
-
(2010)
JAllergy Clin Immunol
, vol.126
, Issue.2
, pp. 415-416
-
-
Pitt, T.J.1
Cisneros, N.2
Kalicinsky, C.3
-
54
-
-
84871619423
-
Bone complications of mastocytosis: a link between clinical and biological characteristics
-
75.e1-75.e7
-
Guillaume N., Desoutter J., Chandesris O., et al. Bone complications of mastocytosis: a link between clinical and biological characteristics. Am J Med 2013, 126(1):75.e1-75.e7.
-
(2013)
Am J Med
, vol.126
, Issue.1
-
-
Guillaume, N.1
Desoutter, J.2
Chandesris, O.3
-
55
-
-
80052303003
-
Bone mineral density, bone turnover markers and fractures in patients with indolent systemic mastocytosis
-
Rossini M., Zanotti R., Bonadonna P., et al. Bone mineral density, bone turnover markers and fractures in patients with indolent systemic mastocytosis. Bone 2011, 49(4):880-885.
-
(2011)
Bone
, vol.49
, Issue.4
, pp. 880-885
-
-
Rossini, M.1
Zanotti, R.2
Bonadonna, P.3
-
56
-
-
84857191019
-
High prevalence of fractures and osteoporosis in patients with indolent systemic mastocytosis
-
van der Veer E., van der Goot W., de Monchy J.G., et al. High prevalence of fractures and osteoporosis in patients with indolent systemic mastocytosis. Allergy 2012, 67(3):431-438.
-
(2012)
Allergy
, vol.67
, Issue.3
, pp. 431-438
-
-
van der Veer, E.1
van der Goot, W.2
de Monchy, J.G.3
-
57
-
-
84882879102
-
Serum IL-31 levels are increased in a subset of patients with mastocytosis and correlate with disease severity in adult patients
-
Hartmann K., Wagner N., Rabenhorst A., et al. Serum IL-31 levels are increased in a subset of patients with mastocytosis and correlate with disease severity in adult patients. JAllergy Clin Immunol 2013, 132(1):232-235.
-
(2013)
JAllergy Clin Immunol
, vol.132
, Issue.1
, pp. 232-235
-
-
Hartmann, K.1
Wagner, N.2
Rabenhorst, A.3
-
58
-
-
84887018065
-
Serum levels of bone cytokines are increased in indolent systemic mastocytosis associated with osteopenia or osteoporosis
-
Rabenhorst A., Christopeit B., Leja S., et al. Serum levels of bone cytokines are increased in indolent systemic mastocytosis associated with osteopenia or osteoporosis. JAllergy Clin Immunol 2013, 132(5):1234-1237.e7.
-
(2013)
JAllergy Clin Immunol
, vol.132
, Issue.5
-
-
Rabenhorst, A.1
Christopeit, B.2
Leja, S.3
-
59
-
-
33344458341
-
Elevated tryptase levels are associated with greater bone density in a cohort of patients with mastocytosis
-
Kushnir-Sukhov N.M., Brittain E., Reynolds J.C., et al. Elevated tryptase levels are associated with greater bone density in a cohort of patients with mastocytosis. Int Arch Allergy Immunol 2006, 139(3):265-270.
-
(2006)
Int Arch Allergy Immunol
, vol.139
, Issue.3
, pp. 265-270
-
-
Kushnir-Sukhov, N.M.1
Brittain, E.2
Reynolds, J.C.3
-
60
-
-
84893045853
-
Management of anaphylaxis: a systematic review
-
Dhami S., Panesar S.S., Roberts G., et al. Management of anaphylaxis: a systematic review. Allergy 2013, 69(2):168-175.
-
(2013)
Allergy
, vol.69
, Issue.2
, pp. 168-175
-
-
Dhami, S.1
Panesar, S.S.2
Roberts, G.3
-
61
-
-
31944443634
-
Second symposium on the definition and management of anaphylaxis: summary report-Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium
-
Sampson H.A., Munoz-Furlong A., Campbell R.L., et al. Second symposium on the definition and management of anaphylaxis: summary report-Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. JAllergy Clin Immunol 2006, 117(2):391-397.
-
(2006)
JAllergy Clin Immunol
, vol.117
, Issue.2
, pp. 391-397
-
-
Sampson, H.A.1
Munoz-Furlong, A.2
Campbell, R.L.3
-
62
-
-
14744282580
-
Epidemiology of life-threatening and lethal anaphylaxis: a review
-
Moneret-Vautrin D.A., Morisset M., Flabbee J., et al. Epidemiology of life-threatening and lethal anaphylaxis: a review. Allergy 2005, 60(4):443-451.
-
(2005)
Allergy
, vol.60
, Issue.4
, pp. 443-451
-
-
Moneret-Vautrin, D.A.1
Morisset, M.2
Flabbee, J.3
-
63
-
-
1542616266
-
Epidemiology of anaphylaxis among children and adolescents enrolled in a health maintenance organization
-
Bohlke K., Davis R.L., DeStefano F., et al. Epidemiology of anaphylaxis among children and adolescents enrolled in a health maintenance organization. JAllergy Clin Immunol 2004, 113(3):536-542.
-
(2004)
JAllergy Clin Immunol
, vol.113
, Issue.3
, pp. 536-542
-
-
Bohlke, K.1
Davis, R.L.2
DeStefano, F.3
-
64
-
-
57149134229
-
The etiology and incidence of anaphylaxis in Rochester, Minnesota: a report from the Rochester Epidemiology Project
-
Decker W.W., Campbell R.L., Manivannan V., et al. The etiology and incidence of anaphylaxis in Rochester, Minnesota: a report from the Rochester Epidemiology Project. JAllergy Clin Immunol 2008, 122(6):1161-1165.
-
(2008)
JAllergy Clin Immunol
, vol.122
, Issue.6
, pp. 1161-1165
-
-
Decker, W.W.1
Campbell, R.L.2
Manivannan, V.3
-
65
-
-
1542286592
-
Incidence of anaphylaxis with circulatory symptoms: a study over a 3-year period comprising 940,000 inhabitants of the Swiss Canton Bern
-
Helbling A., Hurni T., Mueller U.R., et al. Incidence of anaphylaxis with circulatory symptoms: a study over a 3-year period comprising 940,000 inhabitants of the Swiss Canton Bern. Clin Exp Allergy 2004, 34(2):285-290.
-
(2004)
Clin Exp Allergy
, vol.34
, Issue.2
, pp. 285-290
-
-
Helbling, A.1
Hurni, T.2
Mueller, U.R.3
-
66
-
-
0032827928
-
Epidemiology of anaphylaxis in Olmsted County: a population-based study
-
Yocum M.W., Butterfield J.H., Klein J.S., et al. Epidemiology of anaphylaxis in Olmsted County: a population-based study. JAllergy Clin Immunol 1999, 104(2 Pt 1):452-456.
-
(1999)
JAllergy Clin Immunol
, vol.104
, Issue.2 PART 1
, pp. 452-456
-
-
Yocum, M.W.1
Butterfield, J.H.2
Klein, J.S.3
-
67
-
-
33845217089
-
Epidemiology of anaphylaxis: findings of the American College of Allergy, Asthma and Immunology Epidemiology of Anaphylaxis Working Group
-
Lieberman P., Camargo C.A., Bohlke K., et al. Epidemiology of anaphylaxis: findings of the American College of Allergy, Asthma and Immunology Epidemiology of Anaphylaxis Working Group. Ann Allergy Asthma Immunol 2006, 97(5):596-602.
-
(2006)
Ann Allergy Asthma Immunol
, vol.97
, Issue.5
, pp. 596-602
-
-
Lieberman, P.1
Camargo, C.A.2
Bohlke, K.3
-
68
-
-
20144389124
-
Indolent systemic mastocytosis with elevated serum tryptase, absence of skin lesions, and recurrent severe anaphylactoid episodes
-
Florian S., Krauth M.T., Simonitsch-Klupp I., et al. Indolent systemic mastocytosis with elevated serum tryptase, absence of skin lesions, and recurrent severe anaphylactoid episodes. Int Arch Allergy Immunol 2005, 136(3):273-280.
-
(2005)
Int Arch Allergy Immunol
, vol.136
, Issue.3
, pp. 273-280
-
-
Florian, S.1
Krauth, M.T.2
Simonitsch-Klupp, I.3
-
69
-
-
34648816795
-
Prevalence of allergy and anaphylactic symptoms in 210 adult and pediatric patients with mastocytosis in Spain: a study of the Spanish network on mastocytosis (REMA)
-
Gonzalez de Olano D., de la Hoz Caballer B., Nunez Lopez R., et al. Prevalence of allergy and anaphylactic symptoms in 210 adult and pediatric patients with mastocytosis in Spain: a study of the Spanish network on mastocytosis (REMA). Clin Exp Allergy 2007, 37(10):1547-1555.
-
(2007)
Clin Exp Allergy
, vol.37
, Issue.10
, pp. 1547-1555
-
-
Gonzalez de Olano, D.1
de la Hoz Caballer, B.2
Nunez Lopez, R.3
-
70
-
-
84890813890
-
High prevalence of anaphylaxis in patients with systemic mastocytosis-a single-center experience
-
Gulen T., Hagglund H., Dahlen B., et al. High prevalence of anaphylaxis in patients with systemic mastocytosis-a single-center experience. Clin Exp Allergy 2013, 44(1):121-129.
-
(2013)
Clin Exp Allergy
, vol.44
, Issue.1
, pp. 121-129
-
-
Gulen, T.1
Hagglund, H.2
Dahlen, B.3
-
71
-
-
77954340281
-
IgE-mediated anaphylaxis to Hippobosca equina in a patient with systemic mastocytosis
-
Matito A., Bartolome-Zavala B., Alvarez-Twose I., et al. IgE-mediated anaphylaxis to Hippobosca equina in a patient with systemic mastocytosis. Allergy 2010, 65(8):1058-1059.
-
(2010)
Allergy
, vol.65
, Issue.8
, pp. 1058-1059
-
-
Matito, A.1
Bartolome-Zavala, B.2
Alvarez-Twose, I.3
-
72
-
-
84882868503
-
Higher mast cell load decreases the risk of Hymenoptera venom-induced anaphylaxis in patients with mastocytosis
-
van Anrooij B., van der Veer E., de Monchy J.G., et al. Higher mast cell load decreases the risk of Hymenoptera venom-induced anaphylaxis in patients with mastocytosis. JAllergy Clin Immunol 2013, 132(1):125-130.
-
(2013)
JAllergy Clin Immunol
, vol.132
, Issue.1
, pp. 125-130
-
-
van Anrooij, B.1
van der Veer, E.2
de Monchy, J.G.3
-
73
-
-
84873404919
-
Systemic mastocytosis as a risk factor for severe Hymenoptera sting-induced anaphylaxis
-
Alvarez-Twose I., Bonadonna P., Matito A., et al. Systemic mastocytosis as a risk factor for severe Hymenoptera sting-induced anaphylaxis. JAllergy Clin Immunol 2013, 131(2):614-615.
-
(2013)
JAllergy Clin Immunol
, vol.131
, Issue.2
, pp. 614-615
-
-
Alvarez-Twose, I.1
Bonadonna, P.2
Matito, A.3
-
74
-
-
0033393227
-
Mastocytosis associated with severe wasp sting anaphylaxis detected by elevated serum mast cell tryptase levels
-
Biedermann T., Rueff F., Sander C.A., et al. Mastocytosis associated with severe wasp sting anaphylaxis detected by elevated serum mast cell tryptase levels. Br J Dermatol 1999, 141(6):1110-1112.
-
(1999)
Br J Dermatol
, vol.141
, Issue.6
, pp. 1110-1112
-
-
Biedermann, T.1
Rueff, F.2
Sander, C.A.3
-
75
-
-
77949355609
-
Serum concentration of baseline mast cell tryptase: evidence for a decline during long-term immunotherapy for Hymenoptera venom allergy
-
Dugas-Breit S., Przybilla B., Dugas M., et al. Serum concentration of baseline mast cell tryptase: evidence for a decline during long-term immunotherapy for Hymenoptera venom allergy. Clin Exp Allergy 2010, 40(4):643-649.
-
(2010)
Clin Exp Allergy
, vol.40
, Issue.4
, pp. 643-649
-
-
Dugas-Breit, S.1
Przybilla, B.2
Dugas, M.3
-
76
-
-
84903362676
-
Insect stings: clinical features and management
-
Przybilla B., Rueff F. Insect stings: clinical features and management. Dtsch Arztebl Int 2012, 109(13):238-248.
-
(2012)
Dtsch Arztebl Int
, vol.109
, Issue.13
, pp. 238-248
-
-
Przybilla, B.1
Rueff, F.2
-
78
-
-
34249787870
-
Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis
-
Carter M.C., Robyn J.A., Bressler P.B., et al. Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis. JAllergy Clin Immunol 2007, 119(6):1550-1551.
-
(2007)
JAllergy Clin Immunol
, vol.119
, Issue.6
, pp. 1550-1551
-
-
Carter, M.C.1
Robyn, J.A.2
Bressler, P.B.3
-
79
-
-
38949092068
-
High omalizumab dose controls recurrent reactions to venom immunotherapy in indolent systemic mastocytosis
-
Kontou-Fili K. High omalizumab dose controls recurrent reactions to venom immunotherapy in indolent systemic mastocytosis. Allergy 2008, 63(3):376-378.
-
(2008)
Allergy
, vol.63
, Issue.3
, pp. 376-378
-
-
Kontou-Fili, K.1
-
80
-
-
68949208094
-
Prolonged high-dose omalizumab is required to control reactions to venom immunotherapy in mastocytosis
-
Kontou-Fili K., Filis C.I. Prolonged high-dose omalizumab is required to control reactions to venom immunotherapy in mastocytosis. Allergy 2009, 64(9):1384-1385.
-
(2009)
Allergy
, vol.64
, Issue.9
, pp. 1384-1385
-
-
Kontou-Fili, K.1
Filis, C.I.2
-
81
-
-
77953149438
-
Omalizumab monotherapy for bee sting and unprovoked "anaphylaxis" in a patient with systemic mastocytosis and undetectable specific IgE
-
Kontou-Fili K., Filis C.I., Voulgari C., et al. Omalizumab monotherapy for bee sting and unprovoked "anaphylaxis" in a patient with systemic mastocytosis and undetectable specific IgE. Ann Allergy Asthma Immunol 2010, 104(6):537-539.
-
(2010)
Ann Allergy Asthma Immunol
, vol.104
, Issue.6
, pp. 537-539
-
-
Kontou-Fili, K.1
Filis, C.I.2
Voulgari, C.3
-
82
-
-
0033800085
-
C-Kit and c-kit mutations in mastocytosis and other hematological diseases
-
Boissan M., Feger F., Guillosson J.J., et al. c-Kit and c-kit mutations in mastocytosis and other hematological diseases. JLeukoc Biol 2000, 67(2):135-148.
-
(2000)
JLeukoc Biol
, vol.67
, Issue.2
, pp. 135-148
-
-
Boissan, M.1
Feger, F.2
Guillosson, J.J.3
-
83
-
-
84887658376
-
Comprehensive mutational profiling in advanced systemic mastocytosis
-
Schwaab J., Schnittger S., Sotlar K., et al. Comprehensive mutational profiling in advanced systemic mastocytosis. Blood 2013, 122(14):2460-2466.
-
(2013)
Blood
, vol.122
, Issue.14
, pp. 2460-2466
-
-
Schwaab, J.1
Schnittger, S.2
Sotlar, K.3
-
84
-
-
84870766228
-
In aggressive forms of mastocytosis, TET2 loss cooperates with c-KITD816V to transform mast cells
-
Soucie E., Hanssens K., Mercher T., et al. In aggressive forms of mastocytosis, TET2 loss cooperates with c-KITD816V to transform mast cells. Blood 2012, 120(24):4846-4849.
-
(2012)
Blood
, vol.120
, Issue.24
, pp. 4846-4849
-
-
Soucie, E.1
Hanssens, K.2
Mercher, T.3
-
85
-
-
67349145955
-
Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates
-
Tefferi A., Levine R.L., Lim K.H., et al. Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates. Leukemia 2009, 23(5):900-904.
-
(2009)
Leukemia
, vol.23
, Issue.5
, pp. 900-904
-
-
Tefferi, A.1
Levine, R.L.2
Lim, K.H.3
-
86
-
-
84865062086
-
Single nucleotide polymorphism array lesions, TET2, DNMT3A, ASXL1 and CBL mutations are present in systemic mastocytosis
-
Traina F., Visconte V., Jankowska A.M., et al. Single nucleotide polymorphism array lesions, TET2, DNMT3A, ASXL1 and CBL mutations are present in systemic mastocytosis. PloS One 2012, 7(8):e43090.
-
(2012)
PloS One
, vol.7
, Issue.8
-
-
Traina, F.1
Visconte, V.2
Jankowska, A.M.3
-
87
-
-
84862252300
-
Complete response after imatinib mesylate therapy in a patient with well-differentiated systemic mastocytosis
-
Alvarez-Twose I., Gonzalez P., Morgado J.M., et al. Complete response after imatinib mesylate therapy in a patient with well-differentiated systemic mastocytosis. JClin Oncol 2012, 30(12):e126-e129.
-
(2012)
JClin Oncol
, vol.30
, Issue.12
-
-
Alvarez-Twose, I.1
Gonzalez, P.2
Morgado, J.M.3
-
88
-
-
84872800619
-
KIT inhibitor midostaurin in patients with advanced systemic mastocytosis: results of a planned interim analysis of the global CPKC412D2201 trial
-
Gotlib J., Kluin-Nelemans H.C., George T.I., et al. KIT inhibitor midostaurin in patients with advanced systemic mastocytosis: results of a planned interim analysis of the global CPKC412D2201 trial. Blood 2012, 120:799.
-
(2012)
Blood
, vol.120
, pp. 799
-
-
Gotlib, J.1
Kluin-Nelemans, H.C.2
George, T.I.3
-
89
-
-
78649504351
-
Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: a phase 2a study
-
Paul C., Sans B., Suarez F., et al. Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: a phase 2a study. Am J Hematol 2010, 85(12):921-925.
-
(2010)
Am J Hematol
, vol.85
, Issue.12
, pp. 921-925
-
-
Paul, C.1
Sans, B.2
Suarez, F.3
-
90
-
-
70449707323
-
Are we ready to downregulate mast cells?
-
Karra L., Berent-Maoz B., Ben-Zimra M., et al. Are we ready to downregulate mast cells?. Curr Opin Immunol 2009, 21(6):708-714.
-
(2009)
Curr Opin Immunol
, vol.21
, Issue.6
, pp. 708-714
-
-
Karra, L.1
Berent-Maoz, B.2
Ben-Zimra, M.3
-
91
-
-
79960915632
-
Down-regulation of mast cell responses through ITIM containing inhibitory receptors
-
Karra L., Levi-Schaffer F. Down-regulation of mast cell responses through ITIM containing inhibitory receptors. Adv Exp Med Biol 2011, 716:143-159.
-
(2011)
Adv Exp Med Biol
, vol.716
, pp. 143-159
-
-
Karra, L.1
Levi-Schaffer, F.2
-
93
-
-
77950862195
-
Human mast cells express intracellular TRAIL
-
Berent-Maoz B., Salemi S., Mankuta D., et al. Human mast cells express intracellular TRAIL. Cell Immunol 2010, 262(2):80-83.
-
(2010)
Cell Immunol
, vol.262
, Issue.2
, pp. 80-83
-
-
Berent-Maoz, B.1
Salemi, S.2
Mankuta, D.3
-
94
-
-
73949158887
-
Identification of proapoptotic Bim as a tumor suppressor in neoplastic mast cells: role of KIT D816V and effects of various targeted drugs
-
Aichberger K.J., Gleixner K.V., Mirkina I., et al. Identification of proapoptotic Bim as a tumor suppressor in neoplastic mast cells: role of KIT D816V and effects of various targeted drugs. Blood 2009, 114(26):5342-5351.
-
(2009)
Blood
, vol.114
, Issue.26
, pp. 5342-5351
-
-
Aichberger, K.J.1
Gleixner, K.V.2
Mirkina, I.3
-
95
-
-
13544251714
-
Proapoptotic Bcl-2 family member Bim is involved in the control of mast cell survival and is induced together with Bcl-XL upon IgE-receptor activation
-
Alfredsson J., Puthalakath H., Martin H., et al. Proapoptotic Bcl-2 family member Bim is involved in the control of mast cell survival and is induced together with Bcl-XL upon IgE-receptor activation. Cell Death Differ 2005, 12(2):136-144.
-
(2005)
Cell Death Differ
, vol.12
, Issue.2
, pp. 136-144
-
-
Alfredsson, J.1
Puthalakath, H.2
Martin, H.3
-
96
-
-
36048986227
-
The BH3-only protein Puma plays an essential role in cytokine deprivation induced apoptosis of mast cells
-
Ekoff M., Kaufmann T., Engstrom M., et al. The BH3-only protein Puma plays an essential role in cytokine deprivation induced apoptosis of mast cells. Blood 2007, 110(9):3209-3217.
-
(2007)
Blood
, vol.110
, Issue.9
, pp. 3209-3217
-
-
Ekoff, M.1
Kaufmann, T.2
Engstrom, M.3
-
97
-
-
0042926577
-
Expression of Bcl-2 and Bcl-xL in cutaneous and bone marrow lesions of mastocytosis
-
Hartmann K., Artuc M., Baldus S.E., et al. Expression of Bcl-2 and Bcl-xL in cutaneous and bone marrow lesions of mastocytosis. Am J Pathol 2003, 163(3):819-826.
-
(2003)
Am J Pathol
, vol.163
, Issue.3
, pp. 819-826
-
-
Hartmann, K.1
Artuc, M.2
Baldus, S.E.3
-
98
-
-
77956914323
-
The BH3-mimetic ABT-737 induces mast cell apoptosis invitro and invivo: potential for therapeutics
-
Karlberg M., Ekoff M., Huang D.C., et al. The BH3-mimetic ABT-737 induces mast cell apoptosis invitro and invivo: potential for therapeutics. JImmunol 2010, 185(4):2555-2562.
-
(2010)
JImmunol
, vol.185
, Issue.4
, pp. 2555-2562
-
-
Karlberg, M.1
Ekoff, M.2
Huang, D.C.3
-
99
-
-
84897019340
-
The pan-Bcl-2 blocker obatoclax promotes the expression of Puma, Noxa, and Bim mRNA and induces apoptosis in neoplastic mast cells
-
Peter B., Cerny-Reiterer S., Hadzijusufovic E., et al. The pan-Bcl-2 blocker obatoclax promotes the expression of Puma, Noxa, and Bim mRNA and induces apoptosis in neoplastic mast cells. JLeukoc Biol 2013, 95(1):95-104.
-
(2013)
JLeukoc Biol
, vol.95
, Issue.1
, pp. 95-104
-
-
Peter, B.1
Cerny-Reiterer, S.2
Hadzijusufovic, E.3
-
100
-
-
84886788913
-
Dimethylfumarate induces apoptosis in human mast cells
-
Forster A., Preussner L.M., Seeger J.M., et al. Dimethylfumarate induces apoptosis in human mast cells. Exp Dermatol 2013, 22(11):719-724.
-
(2013)
Exp Dermatol
, vol.22
, Issue.11
, pp. 719-724
-
-
Forster, A.1
Preussner, L.M.2
Seeger, J.M.3
-
101
-
-
83455238362
-
Mast cells as targets of pimecrolimus
-
Ma Z., Jiao Z. Mast cells as targets of pimecrolimus. Curr Pharm Des 2011, 17(34):3823-3829.
-
(2011)
Curr Pharm Des
, vol.17
, Issue.34
, pp. 3823-3829
-
-
Ma, Z.1
Jiao, Z.2
-
102
-
-
77953605142
-
Pimecrolimus induces apoptosis of mast cells in a murine model of cutaneous mastocytosis
-
Ma Z., Tovar J.P., Kwong K.Y., et al. Pimecrolimus induces apoptosis of mast cells in a murine model of cutaneous mastocytosis. Int Arch Allergy Immunol 2010, 153(4):413-418.
-
(2010)
Int Arch Allergy Immunol
, vol.153
, Issue.4
, pp. 413-418
-
-
Ma, Z.1
Tovar, J.P.2
Kwong, K.Y.3
-
103
-
-
84874113715
-
Randomized, double-blind, placebo-controlled study of safety and efficacy of miltefosine in antihistamine-resistant chronic spontaneous urticaria
-
Magerl M., Rother M., Bieber T., et al. Randomized, double-blind, placebo-controlled study of safety and efficacy of miltefosine in antihistamine-resistant chronic spontaneous urticaria. JEur Acad Dermatol Venereol 2012, 27(3):e363-e369.
-
(2012)
JEur Acad Dermatol Venereol
, vol.27
, Issue.3
-
-
Magerl, M.1
Rother, M.2
Bieber, T.3
-
104
-
-
84880221843
-
Miltefosine: a novel treatment option for mast cell-mediated diseases
-
Maurer M., Magerl M., Metz M., et al. Miltefosine: a novel treatment option for mast cell-mediated diseases. JDermatolog Treat 2013, 24(4):244-249.
-
(2013)
JDermatolog Treat
, vol.24
, Issue.4
, pp. 244-249
-
-
Maurer, M.1
Magerl, M.2
Metz, M.3
-
105
-
-
58549114489
-
Miltefosine inhibits human mast cell activation and mediator release both invitro and invivo
-
Weller K., Artuc M., Jennings G., et al. Miltefosine inhibits human mast cell activation and mediator release both invitro and invivo. JInvest Dermatol 2009, 129(2):496-498.
-
(2009)
JInvest Dermatol
, vol.129
, Issue.2
, pp. 496-498
-
-
Weller, K.1
Artuc, M.2
Jennings, G.3
-
106
-
-
72749127841
-
Effects of topical treatment with the raft modulator miltefosine and clobetasol in cutaneous mastocytosis: a randomized, double-blind, placebo-controlled trial
-
Hartmann K., Siebenhaar F., Belloni B., et al. Effects of topical treatment with the raft modulator miltefosine and clobetasol in cutaneous mastocytosis: a randomized, double-blind, placebo-controlled trial. Br J Dermatol 2010, 162(1):185-190.
-
(2010)
Br J Dermatol
, vol.162
, Issue.1
, pp. 185-190
-
-
Hartmann, K.1
Siebenhaar, F.2
Belloni, B.3
-
107
-
-
79951495806
-
Mast cell hyperplasia, B-cell malignancy, and intestinal inflammation in mice with conditional expression of a constitutively active kit
-
Gerbaulet A., Wickenhauser C., Scholten J., et al. Mast cell hyperplasia, B-cell malignancy, and intestinal inflammation in mice with conditional expression of a constitutively active kit. Blood 2011, 117(6):2012-2021.
-
(2011)
Blood
, vol.117
, Issue.6
, pp. 2012-2021
-
-
Gerbaulet, A.1
Wickenhauser, C.2
Scholten, J.3
-
108
-
-
41649098497
-
Mast cell functions in the innate skin immune system
-
Metz M., Siebenhaar F., Maurer M. Mast cell functions in the innate skin immune system. Immunobiology 2008, 213(3-4):251-260.
-
(2008)
Immunobiology
, vol.213
, Issue.3-4
, pp. 251-260
-
-
Metz, M.1
Siebenhaar, F.2
Maurer, M.3
-
109
-
-
41549096026
-
Mast cell-driven skin inflammation is impaired in the absence of sensory nerves
-
Siebenhaar F., Magerl M., Peters E.M., et al. Mast cell-driven skin inflammation is impaired in the absence of sensory nerves. JAllergy Clin Immunol 2008, 121(4):955-961.
-
(2008)
JAllergy Clin Immunol
, vol.121
, Issue.4
, pp. 955-961
-
-
Siebenhaar, F.1
Magerl, M.2
Peters, E.M.3
|